The growth of pharma industries has slowed in recent years because of various reasons such as patent expiries, generic competition, drying pipelines, and increasingly stringent regulatory guidelines. Many blockbuster drugs will loose their exclusivity in next 5 years. Therefore, the current economic situation plus the huge generic competition shifted the focus of pharmaceutical companies from the essential medicines to the new business model — niche busters, also called orphan drugs. The purpose of this study is to provide corporate finance professionals, managers, and investors, an overview of the orphan drug market.
This study is part of Gryphon Analytics’ public outreach program aimed at collecting and disseminating information about the important role that life sciences venture investing plays in driving revolutionary pharmaceutical innovation.
Download the Gryphon Analytics Orphan Drug Development Analysis here: